Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG64PE)

• Drug Name: AMG 506 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMG64PE

Molecule-Related Drug Atlas

Drug(s) Targeting Prolyl endopeptidase FAP (FAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talabostat	DM1IZ5D	Constitutional neutropenia	4B00.0	Phase 3	[3]
BIBH 1	DMHYZEK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
Sibrotuzumab	DMT4UC1	Metastatic colorectal cancer	2B91	Phase 2	[4]
NG-641	DMITVHM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
RG7461	DM5OTGR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
PT630	DM9SY8E	Colon cancer	2B90.Z	Preclinical	[7]
FAP5-DM1	DMYFVZ3	Solid tumour/cancer	2A00-2F9Z	Preclinical	[8]
ARI-3099	DMIMD0T	Discovery agent	N.A.	Investigative	[9]
MIP-1231	DM2IGD1	Solid tumour/cancer	2A00-2F9Z	Investigative	[10]
FE-999040	DM3UCWM	Solid tumour/cancer	2A00-2F9Z	Investigative	[10]

Drug(s) Targeting Co-stimulatory molecule 4-1BB (CD137)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Urelumab	DM6RTVG	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[11]
Anti-CD137	DMHVZ27	Solid tumour/cancer	2A00-2F9Z	Phase 2	[12]
MG7-CART	DME6PB0	Acute myeloid leukaemia	2A60	Phase 1/2	[13]
NM21-1480	DMDNJP5	Advanced solid tumour	2A00-2F9Z	Phase 1/2	[14]
CD137 CAR-T Cell	DMHMC19	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[15]
ADG106	DM87H0S	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[16]
CD28 and CD137 CAR-T Cells	DMFGQXB	Acute lymphoblastic leukaemia	2A85	Phase 1	[17]
MCLA-145	DM8CGUV	Lymphoma	2A80-2A86	Phase 1	[18]
GEN1046	DMEWRNZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
INBRX-105	DM2FH10	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Co-stimulatory molecule 4-1BB (CD137)	TTPW9LJ	TNR9_HUMAN	Inhibitor	[2]
Prolyl endopeptidase FAP (FAP)	TTGPQ0F	SEPR_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04049903) Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Amgen.
• [3] Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9.
• [4] A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.
• [5] Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25.
• [8] Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008 Jul 15;14(14):4584-92.
• [9] Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365).
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878).
• [13] ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
• [14] Clinical pipeline report, company report or official report of Numab Therapeutics.
• [15] ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
• [16] Clinical pipeline report, company report or official report of Adagene.
• [17] ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
• [18] Clinical pipeline report, company report or official report of Merus.
• [19] Clinical pipeline report, company report or official report of Genmab.
• [20] Clinical pipeline report, company report or official report of Inhibrx.